Conv. Plasma
Nigella Sativa
Peg.. Lambda

All molnupiravir studies
Meta analysis
Home COVID-19 treatment researchMolnupiravirMolnupiravir (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality 52% Improvement Relative Risk Ventilation 58% Combined death/ventilat.. 40% Hospitalization time 6% Ct<30 28% Molnupiravir  Wong et al.  EARLY TREATMENT Is early treatment with molnupiravir beneficial for COVID-19? PSM retrospective 3,712 patients in China (February - April 2022) Lower mortality (p<0.0001) and progression (p<0.0001) Wong et al., The Lancet Infectious Dis.., May 2022 Favors molnupiravir Favors control

Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study

Wong et al., The Lancet Infectious Diseases, doi:10.1016/S1473-3099(22)00507-2 (date from preprint)
May 2022  
  Source   PDF   All Studies   Meta AnalysisMeta
PSM retrospective 40,776 patients in Hong Kong, showing lower mortality and lower combined mortality, ventilation, ICU, and oxygen therapy with molnupiravir treatment.
Concerns have been raised that the mutagenic mechanism of action may create dangerous variants or cause cancer Hadj Hassine, Huntsman, Marikawa, Swanstrom, Waters, Zibat. Multiple analyses have identifed variants potentially created by molnupiravir Fountain-Jones, Sanderson,
This study includes paxlovid and molnupiravir.
risk of death, 52.0% lower, HR 0.48, p < 0.001, treatment 1,856, control 1,856, propensity score matching.
risk of mechanical ventilation, 58.0% lower, HR 0.42, p = 0.06, treatment 1,856, control 1,856, propensity score matching.
combined death/ventilation/ICU/oxygen, 40.0% lower, HR 0.60, p < 0.001, treatment 1,856, control 1,856, propensity score matching.
hospitalization time, 5.9% lower, relative time 0.94, p = 0.03, treatment 1,856, control 1,856, propensity score matching.
Ct<30, 27.5% lower, HR 0.72, p < 0.001, treatment 1,856, control 1,856, inverted to make HR<1 favor treatment, propensity score matching.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Wong et al., 20 May 2022, retrospective, China, peer-reviewed, 6 authors, study period 26 February, 2022 - 26 April, 2022.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperMolnupiravirAll
Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study
Dr Carlos K H Wong, Ivan C H Au, Kristy T K Lau, Eric H Y Lau, Prof Benjamin J Cowling, Prof Gabriel M Leung
The Lancet Infectious Diseases, doi:10.1016/s1473-3099(22)00507-2
Background Data on the effectiveness of oral antivirals in patients with mild-to-moderate COVID-19 are urgently needed. This retrospective cohort study aimed to evaluate the clinical and virological outcomes associated with molnupiravir or nirmatrelvir-ritonavir use in hospitalised patients with mild-to-moderate COVID-19 during a pandemic wave dominated by the omicron BA.2 subvariant. Methods We analysed data from a territory-wide retrospective cohort of patients in Hong Kong who were hospitalised with a confirmed diagnosis of SARS-CoV-2 infection between Feb 26 and April 26, 2022. Data were extracted from the Hospital Authority, the Department of Health, and the Hong Kong Death Registry. Patients were eligible for inclusion if their admission date was within 3 days before or after confirmation of their COVID-19 diagnosis. Those who were admitted to hospital more than 5 days after symptom onset, were younger than 18 years, had a history of oral antiviral use before admission, required supplemental oxygen on admission, had drug-related contraindications to nirmatrelvir-ritonavir use, or had severe renal or severe liver impairment were excluded. Patients who received the oral antivirals molnupiravir or nirmatrelvir-ritonavir were matched with controls using propensity-score matching in a ratio of 1:1. The primary outcome was all-cause mortality and secondary outcomes included a composite outcome of disease progression (all-cause mortality, initiation of invasive mechanical ventilation [IMV], intensive care unit [ICU] admission, or the need for oxygen therapy) and each of these individual disease progression outcomes, and time to reaching a low viral burden (RT-PCR cycle threshold value ≥30). For each event outcome, crude incidence rates were calculated and hazard ratios (HRs) estimated using Cox regression models. Findings We identified 40 776 patients hospitalised with SARS-CoV-2 infection during the study period, with a mean follow-up of 41•3 days (total 925 713 person-days). After exclusions and propensity-score matching, we included 1856 molnupiravir recipients and 1856 matched controls, and 890 nirmatrelvir-ritonavir recipients and 890 matched controls. A lower risk of all-cause mortality was observed in molnupiravir recipients (crude incidence rate per 10 000 person-days 19•98 events [95% CI 16•91-23•45]) versus matched controls (38•07 events [33•85-42•67]; HR 0•48 [95% CI 0•40-0•59], p<0•0001) and in nirmatrelvir-ritonavir recipients (10•28 events [7•03-14•51]) versus matched controls (26•47 events [21•34-32•46]; HR 0•34 [0•23-0•50], p<0•0001). Oral antiviral recipients also had lower risks of the composite disease progression outcome (molnupiravir HR 0•60 [95% CI 0•52-0•69], p<0•0001; nirmatrelvir-ritonavir 0•57 [0•45-0•72], p<0•0001) and need for oxygen therapy (molnupiravir 0•69 [0•57-0•83], p=0•0001; nirmatrelvir-ritonavir 0•73 [0•54-0•97], p=0•032) compared with controls. Time to achieving a low viral burden was..
Arbel, Sagy, Hoshen, Oral nirmatrelvir and severe COVID-19 outcomes during the omicron surge, doi:10.21203/
Arribas, Bhagani, Lobo, Randomized trial of molnupiravir or placebo in patients hospitalized with COVID-19, NEJM Evidence
Austin, Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations, Biom J
Bernal, Da Silva, Musungaie, Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients, N Engl J Med
Bojkova, Widera, Ciesek, Wass, Michaelis et al., Reduced interferon antagonism but similar drug sensitivity in omicron variant compared to delta variant of SARS-CoV-2 isolates, Cell Res
Fischer Wa 2nd, Eron, Jr, Holman, A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus, Sci Transl Med
Hammond, Leister-Tebbe, Gardner, Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19, N Engl J Med
Hetero, Hetero announces interim clinical results from phase III clinical trials of molnupiravir conducted in India
Johnson, Puenpatom, Moncada, Effect of molnupiravir on biomarkers, respiratory interventions, and medical services in COVID-19: a randomized, placebo-controlled trial, Ann Intern Med, doi:10.7326/m22-0729
Leyrat, Seaman, White, Propensity score analysis with partially observed covariates: how should multiple imputation be used?, Stat Methods Med Res
Li, Wang, Lavrijsen, SARS-CoV-2 omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination, Cell Res
Merck, Merck and Ridgeback to present data demonstrating that treatment with Lagevrio (molnupiravir) was associated with more rapid elimination of infectious SARS-CoV-2 than placebo
Monedero, Gea, Castro, Early corticosteroids are associated with lower mortality in critically ill patients with COVID-19: a cohort study, Crit Care
Mótyán, Mahdi, Hoffka, Tőzsér, Potential resistance of SARS-CoV-2 main protease (Mpro) against protease inhibitors: lessons learned from HIV-1 protease, Int J Mol Sci
Najjar-Debbiny, Gronich, Weber, Effectiveness of paxlovid in reducing severe COVID-19 and mortality in high risk patients, Clin Infect Dis, doi:10.1093/cid/ciac443
Renoux, Azoulay, Suissa, Biases in evaluating the safety and effectiveness of drugs for the treatment of COVID-19: designing real-world evidence studies, Am J Epidemiol
Saravolatz, Depcinski, Sharma, Molnupiravir and nirmatrelvir-ritonavir: oral COVID antiviral drugs, Clin Infect Dis, doi:10.1093/cid/ciac180
Singh, Singh, Singh, Misra, Molnupiravir in COVID-19: a systematic review of literature, Diabetes Metab Syndr
Soriano, De-Mendoza, Edagwa, Oral antivirals for the prevention and treatment of SARS-CoV-2 infection, AIDS Rev
Takashita, Kinoshita, Yamayoshi, Efficacy of antibodies and antiviral drugs against COVID-19 omicron variant, N Engl J Med
Takashita, Kinoshita, Yamayoshi, Efficacy of antiviral agents against the SARS-CoV-2 omicron subvariant BA.2, N Engl J Med
Ullrich, Ekanayake, Otting, Nitsche, Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir, Bioorg Med Chem Lett
Vangeel, Chiu, Jonghe, Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 omicron and other variants of concern, Antiviral Res
Waters, Warren, Hughes, Lewis, Zhang, Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of molnupiravir, Environ Mol Mutagen
White, Royston, Wood, Multiple imputation using chained equations: issues and guidance for practice, Stat Med
Who, Therapeutics and COVID-19: living guideline
Wong, Lau, Au, Xiong, Lau et al., Clinical improvement, outcomes, antiviral activity, and costs associated with early treatment with remdesivir for patients with coronavirus disease 2019 (COVID-19), Clin Infect Dis
Zhou, Hill, Sarkar, β-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells, J Infect Dis
Zou, Peng, Shu, Antiviral efficacy and safety of molnupiravir against omicron variant infection: a randomized controlled clinical trial, Front Pharmacol
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop